Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Assets Average (2016 - 2025)

Northwest Biotherapeutics' Assets Average history spans 15 years, with the latest figure at $55.9 million for Q4 2025.

  • Quarterly results put Assets Average at $55.9 million for Q4 2025, up 99.64% from a year ago — trailing twelve months through Dec 2025 was $55.9 million (up 99.64% YoY), and the annual figure for FY2025 was $54.0 million, up 97.86%.
  • Assets Average for Q4 2025 was $55.9 million at Northwest Biotherapeutics, up from $30.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $55.9 million in Q4 2025 to a low of $27.1 million in Q1 2025.
  • The 5-year median for Assets Average is $29.8 million (2023), against an average of $31.4 million.
  • The sharpest move saw Assets Average surged 229.66% in 2021, then dropped 12.09% in 2024.
  • Year by year, Assets Average stood at $34.2 million in 2021, then fell by 8.72% to $31.2 million in 2022, then fell by 4.91% to $29.7 million in 2023, then dropped by 5.57% to $28.0 million in 2024, then surged by 99.64% to $55.9 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $55.9 million, $30.1 million, and $28.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.